Arcturus Is Developing **ARCT-810** As a Potential Therapy for OTC Deficiency

What is **ARCT-810**?

ARCT-810 is an investigational mRNA treatment developed to target the root cause of OTC deficiency. The mRNA in ARCT-810 is designed to act as a template for making OTC enzyme to help remove excess ammonia from the body.

When someone has OTC deficiency, ammonia is not removed from the body but instead builds up, which can lead to serious illness or life-threatening symptoms.

ARCT-810 CONSISTS OF TWO KEY PARTS



Messenger RNA, or mRNA, carries the template for making the OTC enzyme.

Lipid nanoparticle sphere contains tiny fat particles that protect the mRNA and allow it to be delivered into liver.

Together, we believe ARCT-810 can enable the body to make OTC enzymes and remove excess ammonia.

ARCT-810 IS DIFFERENT THAN GENE THERAPY

The mRNA appears to be short-lived and does not alter one's genes. ARCT-810 does not use viruses to carry the mRNA to the liver cells. Instead, by using LUNAR® technology, ARCT-810 addresses the root cause of OTC deficiency by helping to produce OTC enzymes using the cell's own processes.

Scan the QR code to learn more about the **ARCT-810-04 STUDY** or visit ClinicalTrials.gov **NCT06488313**

For all other questions, please contact **Community@ArcturusRx.com.**

ARCTURUS® therapeutics

Arcturus Therapeutics | Arcturus Therapeutics | @ArcturusRx

www.ArcturusRx.com | Community@ArcturusRx.com

© 2024 Arcturus Therapeutics, Inc. All rights reserved. | May 2024

LUNAR-OTC